Saccharomyces boulardii CNCM I-745 probiotic does not alter the pharmacokinetics of amoxicillin
- 5 March 2020
- journal article
- research article
- Published by Walter de Gruyter GmbH in Drug Metabolism and Personalized Therapy
Abstract
Background: Probiotics are live microbial organisms that provide benefit to the host while co-habitating in the gastrointestinal tract. Probiotics are safe, available over the counter, and have clinical benefit by reducing the number of antibiotic-associated diarrhea days. Prescriptions from providers and direct consumer demand of probiotics appear to be on the rise. Several recent animal studies have demonstrated that probiotics may have significant effect on absorption of co-administered drugs. However, to date, most probiotic-drug interaction studies in animal models have been limited to bacterial probiotics and nonantibiotic drugs. Methods: We performed a traditional pharmacokinetic mouse study examining the interactions between a common commercially available yeast probiotic, Saccharomyces boulardii CNCM I-745 (Florastor®) and an orally administered amoxicillin. Results: We showed that there were no significant differences in pharmacokinetic parameters (half-life, area under the curve, peak concentrations, time to reach maximum concentration, elimination rate constant) of amoxicillin between the probiotic treated and untreated control groups. Conclusions: Altogether, our findings suggest that coadministration or concurrent use of S. boulardii probiotic and amoxicillin would not likely alter the efficacy of amoxicillin therapy.Keywords
This publication has 41 references indexed in Scilit:
- Upregulation of P-glycoprotein by probiotics in intestinal epithelial cells and in the dextran sulfate sodium model of colitis in miceAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2011
- Antibiotic Dose Impact on Resistance Selection in the Community: a Mathematical Model of β-Lactams and Streptococcus pneumoniae DynamicsAntimicrobial Agents and Chemotherapy, 2010
- Transduction pathways regulating the trophic effects ofSaccharomyces boulardiiin rat intestinal mucosaScandinavian Journal of Gastroenterology, 2009
- Variations in Amoxicillin Pharmacokinetic/Pharmacodynamic Parameters May Explain Treatment Failures in Acute Otitis MediaPediatric Drugs, 2009
- Antibiotic resistance—What’s dosing got to do with it?Critical Care Medicine, 2008
- Butyrate Transcriptionally Enhances Peptide Transporter PepT1 Expression and ActivityPLOS ONE, 2008
- Soluble factors fromLactobacillus GGactivate MAPKs and induce cytoprotective heat shock proteins in intestinal epithelial cellsAmerican Journal of Physiology-Cell Physiology, 2006
- Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in miceGut, 2006
- Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC)Gut, 2003
- Disposition kinetics of Saccharomyces boulardii in man and ratBiopharmaceutics & Drug Disposition, 1989